To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
1 other identifier
interventional
455
2 countries
56
Brief Summary
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 1998
Longer than P75 for phase_3
56 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 1998
CompletedFirst Submitted
Initial submission to the registry
August 30, 2005
CompletedFirst Posted
Study publicly available on registry
September 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2005
CompletedNovember 6, 2009
November 1, 2009
August 30, 2005
November 5, 2009
Conditions
Outcome Measures
Primary Outcomes (1)
Safety Efficacy
Interventions
Eligibility Criteria
You may qualify if:
- Have received double-blind study medication and wish to receive open-label pregabalin.
You may not qualify if:
- Cannot have absence seizures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (56)
Pfizer Investigational Site
Birmingham, Alabama, 35249, United States
Pfizer Investigational Site
Birmingham, Alabama, 35255, United States
Pfizer Investigational Site
Birmingham, Alabama, 35294-0021, United States
Pfizer Investigational Site
Phoenix, Arizona, 85006, United States
Pfizer Investigational Site
Tucson, Arizona, 85712-2809, United States
Pfizer Investigational Site
Tucson, Arizona, 85712, United States
Pfizer Investigational Site
Little Rock, Arkansas, 72205, United States
Pfizer Investigational Site
Los Angeles, California, 90033, United States
Pfizer Investigational Site
Pasadena, California, 91105, United States
Pfizer Investigational Site
Gainesville, Florida, 32608-1197, United States
Pfizer Investigational Site
Gainesville, Florida, 32610, United States
Pfizer Investigational Site
Miami, Florida, 33136, United States
Pfizer Investigational Site
Plantation, Florida, 33317, United States
Pfizer Investigational Site
Spring Hill, Florida, 34609, United States
Pfizer Investigational Site
Tallahassee, Florida, 32308, United States
Pfizer Investigational Site
Chicago, Illinois, 60612, United States
Pfizer Investigational Site
Springfield, Illinois, 62702, United States
Pfizer Investigational Site
Springfield, Illinois, 62704, United States
Pfizer Investigational Site
Indianapolis, Indiana, 46202, United States
Pfizer Investigational Site
Indianapolis, Indiana, 46254, United States
Pfizer Investigational Site
Iowa City, Iowa, 52242, United States
Pfizer Investigational Site
Kansas City, Kansas, 66160-7314, United States
Pfizer Investigational Site
Kansas City, Kansas, 66160, United States
Pfizer Investigational Site
Louisville, Kentucky, 40205, United States
Pfizer Investigational Site
Baltimore, Maryland, 21201, United States
Pfizer Investigational Site
Baltimore, Maryland, 21224, United States
Pfizer Investigational Site
Greenbelt, Maryland, 20770, United States
Pfizer Investigational Site
Boston, Massachusetts, 02130, United States
Pfizer Investigational Site
Boston, Massachusetts, 02215, United States
Pfizer Investigational Site
Ann Arbor, Michigan, 48108, United States
Pfizer Investigational Site
Ann Arbor, Michigan, 48109, United States
Pfizer Investigational Site
Saint Paul, Minnesota, 55102, United States
Pfizer Investigational Site
Chesterfield, Missouri, 63017, United States
Pfizer Investigational Site
Columbia, Missouri, 65212, United States
Pfizer Investigational Site
St Louis, Missouri, 63110-1092, United States
Pfizer Investigational Site
St Louis, Missouri, 63110, United States
Pfizer Investigational Site
Lebanon, New Hampshire, 03756, United States
Pfizer Investigational Site
New York, New York, 10016, United States
Pfizer Investigational Site
New York, New York, 10032, United States
Pfizer Investigational Site
Rochester, New York, 14642, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, 27157, United States
Pfizer Investigational Site
Cleveland, Ohio, 44195, United States
Pfizer Investigational Site
Columbus, Ohio, 43210, United States
Pfizer Investigational Site
Portland, Oregon, 97227, United States
Pfizer Investigational Site
Nashville, Tennessee, 37232, United States
Pfizer Investigational Site
Dallas, Texas, 75230, United States
Pfizer Investigational Site
San Antonio, Texas, 78229, United States
Pfizer Investigational Site
Bennington, Vermont, 05201, United States
Pfizer Investigational Site
Edmonton, Alberta, T5H 3V9, Canada
Pfizer Investigational Site
Edmont, Alberta, T5G 0B7, Canada
Pfizer Investigational Site
Vancouver, British Columbia, V52 1M9, Canada
Pfizer Investigational Site
Vancouver, British Columbia, V67 1Y6, Canada
Pfizer Investigational Site
London, Ontario, N6A 5A5, Canada
Pfizer Investigational Site
Ottawa, Ontario, K1H 8L6, Canada
Pfizer Investigational Site
Toronto, Ontario, M4Y 1J3, Canada
Pfizer Investigational Site
Montreal, Quebec, H3A 2B4, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 30, 2005
First Posted
September 1, 2005
Study Start
July 1, 1998
Study Completion
October 1, 2005
Last Updated
November 6, 2009
Record last verified: 2009-11